Clinical evaluation of efficacy and safety of α-keto analogs of essential amino acids supplementation in patients of chronic kidney disease

Irfan A. Khan1*, Mohammad Nasiruddin1, Shahzad F. Haque2, Rahat A. Khan1

INTRODUCTION

Chronic kidney disease (CKD) is a public health problem worldwide. According to the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, CKD is defined as: kidney damage or glomerular filtration rate (GFR)<60 ml/min/1.73 m² for 3 months or more, irrespective of the cause. The prevalence of CKD in Screening and Early Evaluation of Kidney Disease (SEEK)-India cohort was approximately 17.2% with ~6% have CKD stage 3 or worse. The financial burden of renal replacement therapy (RRT) is increased with increasing prevalence of CKD; CKD related CVD and end stage renal disease (ESRD). It is estimated that around 100,000 new patients of ESRD require RRT annually in India. Low protein diet (LPD) (0.6 g/kg BW/day) as well as very low protein diet (VLPD) (0.3 g/kg BW/day) decreases the accumulation of nitrogen waste products while maintaining an adequate nutritional status. Hence, secondary problems such as metabolic acidosis, bone disease and insulin resistance, as well as proteinuria and deterioration of renal function are reduced.

α-Keto analogs of essential amino acids/keto amino acids (KAA) are nitrogen free analogs of essential amino acids. The use of KAA in association with a LPD or VLPD allows a reduced intake of nitrogen, while avoiding the deleterious consequences of inadequate dietary protein intake and malnourishment. The aim of our study was to evaluate the efficacy and safety of KAA supplementation in patients of CKD.

ABSTRACT

Background: The objective was to evaluate the efficacy and safety of α-keto analogs of essential amino acids (KAA) as a supplement in chronic kidney disease (CKD).

Methods: A prospective comparative study was conducted in patients of CKD of a tertiary care center of North India. Patients were randomly divided into two interventional groups. Group I (control) was advised conservative management and placebo while Group II (KAA) given conservative management along with KAA (600 mg, thrice daily) for 12 weeks. Hemogram, renal function tests, lipid profiles were done, and adverse effects were recorded at 0, 4, 8, and 12 weeks of treatment.

Results: There was progressive improvement in clinical features in both groups after 12 weeks of treatment, but KAA group showed more marked improvement as compared with the control group. Both groups showed gradual improvement in the biochemical parameters as compared to their pre-treated values, which was more marked in KAA supplemented group. There was a reduction in blood glucose, blood urea, serum creatinine, and 24 h total urine protein. There was an increase in hemoglobin, 24 h total urine volume and glomerular filtration rate. KAA group showed significant (p<0.05) improvement in lipid profiles as compared with the control group. There was no statistical difference in two groups with respect to side-effects (p>0.05).

Conclusion: KAA supplementation along with conservative management is efficacious and safe in preventing the progression of disease in patients of CKD.

Keywords: Keto amino acids, Glomerular filtration rate, Conservative management, End stage renal disease
METHODS

Patients

The present study was conducted from June 2012 to September 2013 in patients of CKD attending Renal Clinic or admitted in IPD of a tertiary care center of North India. It was a randomized, prospective, double-blinded, and parallel group study. The approval for the study was taken Institutional Ethics Committee, J.N. Medical College, A.M.U. Aligarh. The study is registered under Clinical Trial Registry of India with registration number CTRI/2012/09/002947 (Registered on: 03/09/2012). Written and informed consent was taken from all patients before enrolling in the study. The diagnosis of CKD was made on the basis of detailed clinical history, physical examination, and investigations (renal function tests).

The diagnostic criteria for CKD according to the National Kidney Foundation’s K/DOQI guidelines (2002)\(^2\) is: kidney damage for ≥3 months or GFR <60 mL/min/1.73 m\(^2\) for ≥3 months with or without kidney damage.

Inclusion criteria

Patients having CKD (stage 3-4), age 20-60 years and of either sex were included in the study.

Exclusion criteria

Patients of ESRD, on dialysis, pregnant, terminally ill, immunocompromised or severe renal pathology such as malignancy were excluded from the study.

Sample size (n)

\[ n = \left( \frac{z^2 \times \sigma^2}{e^2} \right) q \times (1-q), \]

where \( z \) = level of the confidence interval at 95%, \( \sigma \) = standard deviation; \( e \) = acceptable error; \( p \) = prevalence (prevalence assumed as 17.2% according to SEEK-India cohort study); \( q = 1 - p \). Hence, sample size (n) = \( \left( \frac{(1.96 \times 1.96) \times (0.09 \times 0.09)}{(0.172 \times 0.828)} \right) = 67.54 \). Hence, sample size of 68 is minimum required for each group. Taking into consideration a 15% dropout rate, 80 patients were recruited in each group.

Study design

Of 180 assessed patients, 160 patients were enrolled in the study. Fifteen patients (9 of Group I and 6 of Group II) failed to report on subsequent visits and were excluded from the study. Enrolled patients were randomized into two groups at a ratio of 1:1 using table generated by random allocation software. The randomization table had 20 subjects in each block to minimize the disparity between the three groups with respect to the number of patients at any time of study. After final diagnosis, applying inclusion and exclusion criteria, patients were included in the study. Group I (control) patients received conservative management of CKD along with placebo while Group II (KAA) patients received conservative management of CKD along with KAA tablet (600 mg) thrice daily (Figure 1). Both groups received treatment for 12 weeks. In conservative management treatment given was renal diet and telmisartan (40 mg once daily). KAA contains α-keto analogs of DL-isoleucine, leucine, phenylalanine, valine, DL-methionine, L-lysine acetate, L-threonine, L-tryptophan, L-histidine, L-tyrosine as their calcium salts.

All the enrolled patients were regularly followed with hemogram, renal function tests, and lipid profile tests at 0, 4, 8, and 12, weeks of treatment.

Safety assessments

All adverse events experienced by a patient or observed by the investigator were recorded on standard adverse drug reaction (ADR) reporting forms of CDSCO at each visit. ADRs causality assessment was done using Naranjo Scale\(^1\) and severity assessment by Modified Hartwig & Siegel Scale.\(^2\) A physical examination, including vital signs, was performed at the start of study and at each visit. Additional routine laboratory safety test such as liver function tests (LFT), electrocardiography, and chest X-ray were performed wherever required. All the ADRs were reported to the ADR monitoring center of the college.

Statistical analysis

The values were expressed as mean ± SD. Statistical significance between pre- and post-treatment values in each group was calculated using Student’s paired t-test. Statistical significance between groups was calculated using unpaired t-test. \( p < 0.05 \) was considered to be significant. Statistical analysis was done using SPSS-20 software.

RESULTS

Seventy-one (41 M, 30 F) patients mean aged 45 years (range 22-58 years) were of Group I and 74 (44 M, 30 F) patients mean aged 45 years (range 21-59 years) were of Group II. The distribution of patients was almost similar in both groups. None of the patient in either group required dialysis, and there was no mortality in either group. As per GFR (mL/min/1.73 m\(^2\)), patients belonged to stage 3 (19 and 22 in Groups I and II, respectively) and stage 4 (52 in each group) CKD in both groups. The causes of CKD in Groups I and II were: diabetic nephropathy (45.07% and 43.24%), hypertensive nephropathy (18.30% and 20.27%), chronic glomerulonephritis (11.26% and 10.81%), tubulointerstitial nephritis (8.45% and 5.40%), autosomal dominant polycystic kidney disease (4.22% and 5.40%) and unknown cause (12.67% and 14.86%).

In the present study, the clinical features found in patients at admission were: anorexia, nausea, vomiting, weakness,
weight loss, and headache, pruritus, swelling over body, oliguria, anemia, hypertension, and dyspnea. The clinical features were almost similar at 0 week in both groups. There was gradual improvement in clinical features in both groups after 12 weeks of treatment, but it was more marked in KAA group.

There was progressive decrease in both systolic and diastolic blood pressure toward normal in both groups. As compared with the control group, KAA group showed significant (p<0.05) reduction in both systolic and diastolic blood pressure after 12 weeks of the treatment (Table 1).

There was progressive improvement in lipid profile after 12 weeks in both groups, which was significant (p<0.05) in KAA group as compared with control (Table 1).

The total leukocyte count, differential leukocyte count, and platelet count remained within normal limits at the end of 12 weeks of treatment in both groups.

There was progressive improvement in various biochemical parameters in both groups; KAA group showed maximum improvement. As compared with the control group, KAA group showed a significant increase in hemoglobin percent (p<0.05), decrease in fasting and post-prandial blood glucose (p<0.001), decrease in blood urea (p<0.001) and decrease in serum creatinine (p<0.05) at 12 weeks. There was a progressive increase in serum sodium in both groups, which was statistically not significant; however, there was a decrease in serum potassium in both groups, which was significant (p<0.001) in KAA group as compared with control. There was a significant increase in serum calcium (p<0.001), decrease in total urine protein (p<0.01), increase in total urine volume (p<0.001) and increase in GFR (p<0.001) after 12 weeks of treatment in KAA group as compared with the control group (Table 2).

The ADRs occurrence was not significantly different between control and KAA groups. According to Modified Hartwig & Siegel Scale, the ADRs were mild (no hospitalization, no change of therapy and no additional treatment) in severity in both groups. No adverse event was of acute onset (within 60 min). On Naranjo’s Scale, the ADRs were possible (Score = 1-4) in 12 cases and probable (Score = 5-8) in 11 cases with the control group while possible (Score = 1-4) in 15 cases and probable (Score = 5-8) in 7 cases with KAA group (Table 3).

**DISCUSSION**

CKD is an emerging chronic disease globally due to rapidly increasing incidence of diabetes and hypertension worldwide. CKD leads to premature morbidity and mortality and hampers quality of life. In India, CKD is a major problem for both health sector and economy. The ideal treatment for CKD-ESRD is RRT which includes renal transplantation and maintenance dialysis. More than 100,000 new patients enter RRT annually in India. Because of meager resources, only 10% of Indian ESRD patients receive any RRT. The monthly cost of hemodialysis is $300, whereas continuous ambulatory peritoneal dialysis costs $600. The cost of transplant is $8900 in the 1st year, which declines later to $3000 annually. Among the RRT options, renal transplant is the preferred choice as it is cost-effective and offers better quality of life, but still only a fraction of Indians can afford it.

**Table 1: Blood pressure and lipid profile tests in control and KAA groups before and after 12 weeks of treatment.**

| Parameter | Group | 0 week mean±SD | 12 weeks mean±SD | Percentage change after 12 weeks |
|-----------|-------|----------------|------------------|----------------------------------|
| SBP (mm Hg) | I | 150.40±17.62 | 136.62±16.45 | (−) 9.16 |
|           | II | 156.78±22.86 | 130.85±9.58 | (−) 16.53 |
| DBP (mm Hg) | I | 87.32±10.43 | 85.98±9.65 | (−) 1.53 |
|           | II | 88.02±12.40 | 83.80±10.71 | (−) 4.79 |
| T.Ch. (mg/dL) | I | 196.46±29.83 | 191.99±23.24 | (−) 2.27 |
|           | II | 197.27±29.03 | 185.18±22.42 | (−) 6.12 |
| TG (mg/dL) | I | 130.89±21.52 | 120.28±20.98 | (−) 8.10 |
|           | II | 132.17±19.94 | 112.50±18.68 | (−) 14.88 |
| HDL (mg/dL) | I | 48.00±5.81 | 49.13±7.47 | (+) 2.35 |
|           | II | 46.44±5.69 | 49.33±7.26 | (+) 6.62 |
| LDL (mg/dL) | I | 130.82±23.01 | 129.13±17.86 | (−) 1.29 |
|           | II | 132.30±21.72 | 125.02±16.88 | (−) 5.50 |
| VLDL (mg/dL) | I | 16.45±2.75 | 14.82±2.17 | (−) 9.90 |
|           | II | 15.63±1.99 | 13.70±1.73 | (−) 12.34 |

Values are mean±SD, p<0.05 was considered significant, a: p<0.05, b: p<0.01, c: p<0.001 compared to 0 week value of respective group, 1: p<0.05, 2: p<0.01, 3: p<0.001 compared to control group, I: Control, II: KAA, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, T.Ch.: Total cholesterol, TG: Triglyceride, HDL: High density lipoprotein, LDL: Low density lipoprotein, VLDL: Very low density lipoprotein, −: Decrease, +: Increase, KAA: Keto analogs of essential amino acids
Conservative management is very important to prevent CKD and to prevent progression of CKD to ESRD. It delays the progressive deterioration of renal function. It provides only symptomatic relief. Hence, newer treatment modalities are being searched, which can halt nephron damage, delay the development of ESRD, and be cost-effective.

Richards et al. suggested that KAA might be useful in the treatment of uremia. According to Teplan, KAA get transaminated by taking nitrogen from non-essential amino acids, thereby decreasing the formation of urea by re-using the amino group.

Ketoacids reduce protein degradation and urinary protein excretion. Ell et al. showed that ketoacid supplements produced a reduction of plasma urea, urea synthesis and urea excretion and an improvement in nitrogen balance in patients of chronic renal failure.

KAA had good glycemic control, improved insulin sensitivity and reduced hyperinsulinemia. Chen et al. showed a significant reduction in tumor necrosis factor-α, C-reactive protein and adiponectin on keto acid supplementation in type 2 diabetic nephropathy. These might be the probable mechanisms for beneficial effects of KAA in our study.

Di Iorio et al. showed that supplementation of KAA along with LPD in CKD patients resulted in a reduction of about 35% of the erythropoietin dose required to maintain the target hemoglobin levels. In moderate to advanced CKD, VLPD has an antihypertensive effect likely due to

Table 2: Haemogram and renal function tests in control and KAA groups before and after 12 weeks of treatment.

| Parameter        | Group | 0 week mean±SD | 12 weeks mean±SD | Percentage change after 12 weeks |
|------------------|-------|----------------|------------------|---------------------------------|
| Hb % (g/dL)      | I     | 7.91±1.93      | 8.91±1.48        | (+) 12.64                       |
|                  | II    | 7.84±1.10      | 9.39±0.87        | (+) 19.77                       |
| FBG (mg/dL)      | I     | 130.05±42.90   | 113.78±14.3      | (−) 12.51                       |
|                  | II    | 131.28±44.31   | 104.00±8.46      | (−) 20.78                       |
| PPBG (mg/dL)     | I     | 184.95±61.17   | 157.56±23.20     | (−) 14.80                       |
|                  | II    | 181.28±55.22   | 143.40±12.83     | (−) 20.89                       |
| B.Urea (mg/dL)   | I     | 107.16±35.85   | 79.78±24.79      | (−) 25.55                       |
|                  | II    | 106.73±27.72   | 66.07±19.29      | (−) 38.09                       |
| S.Cr. (mg/dL)    | I     | 4.44±1.64      | 3.33±1.37        | (−) 25.00                       |
|                  | II    | 4.68±1.86      | 2.83±1.10        | (−) 39.52                       |
| K⁺ (mEq/L)       | I     | 4.87±0.49      | 4.63±0.41        | (−) 4.92                        |
|                  | II    | 4.80±0.46      | 4.22±0.44        | (−) 12.08                       |
| Ca²⁺ (mg/dL)     | I     | 8.65±1.05      | 8.89±1.00        | (+) 2.77                        |
|                  | II    | 8.70±1.11      | 9.54±0.91        | (+) 9.65                        |
| TUP (g/day)      | I     | 3.03±1.29      | 2.43±0.97        | (−) 19.80                       |
|                  | II    | 3.34±0.88      | 2.06±0.61        | (−) 38.34                       |
| TUV (mL/day)     | I     | 1454.36±221.53 | 1736.76±176.04   | (+) 19.41                       |
|                  | II    | 1457.46±179.48 | 1943.23±204.1    | (+) 33.32                       |
| GFR (mL/min)     | I     | 19.0±1.17      | 23.3±1.63        | (+) 22.6                        |
|                  | II    | 19.7±1.86      | 29.4±3.68        | (+) 49.2                        |

Values are mean±SD, p<0.05 was considered significant, a: p<0.05, b: p<0.01, c: p<0.001 compared to 0 week value of respective group, I: Control, II: KAA, Hb %: Hemoglobin percent, FBG: Fasting blood glucose, PPBG: Postprandial blood glucose, B. Urea: Blood urea, S. Cr.: Serum creatinine, K⁺: Serum potassium, Ca²⁺: Serum calcium, TUP: 24 h Total urine protein, TUV: 24 h total urine volume, GFR: Glomerular filtration rate, −: Decrease, +: Increase, KAA: Keto analogs of essential amino acids

Table 3: Comparison of adverse drug reactions (ADRs) between Control and Keto amino acid group.

| ADR recorded      | Control (n=71) | KAA (n=74) | Significance (2-tailed) |
|-------------------|---------------|------------|------------------------|
| Nausea            | 5             | 3          | 0.494                  |
| Vomiting          | 4             | 2          | 0.442                  |
| Diarrhea          | 5             | 2          | 0.275                  |
| Constipation      | 0             | 2          | 0.497                  |
| Anorexia          | 4             | 3          | 0.719                  |
| Excessive thirst  | 0             | 3          | 0.245                  |
| Abdominal pain    | 1             | 2          | 1.000                  |
| Muscle and joint pain | 0     | 1          | 1.000                  |
| Headache          | 3             | 1          | 0.366                  |
| Rashes            | 0             | 1          | 1.000                  |
| Altered taste     | 0             | 1          | 1.000                  |
| Weakness          | 1             | 0          | 0.497                  |
| Frequent urination| 0             | 1          | 1.000                  |

p<0.05 was considered significant; Fisher’s exact test was applied. KAA: Keto analogs of essential amino acids

Progressive deterioration of renal function. It provides only symptomatic relief. Hence, newer treatment modalities are being searched, which can halt nephron damage, delay the development of ESRD, and be cost-effective.

Richards et al. suggested that KAA might be useful in the treatment of uremia. According to Teplan, KAA get transaminated by taking nitrogen from non-essential amino acids, thereby decreasing the formation of urea by re-using the amino group. Ketocids reduce protein degradation and urinary protein excretion. Ell et al. showed that ketoacid supplements produced a reduction of plasma urea, urea synthesis and urea excretion and an improvement in nitrogen balance in patients of chronic renal failure. KAA had good glycemic control, improved insulin sensitivity and reduced hyperinsulinemia. Chen et al. showed a significant reduction in tumor necrosis factor-α, C-reactive protein and adiponectin on keto acid supplementation in type 2 diabetic nephropathy. These might be the probable mechanisms for beneficial effects of KAA in our study.

Di Iorio et al. showed that supplementation of KAA along with LPD in CKD patients resulted in a reduction of about 35% of the erythropoietin dose required to maintain the target hemoglobin levels. In moderate to advanced CKD, VLPD has an antihypertensive effect likely due to
KAA showed beneficial effects in CKD stage 4, 5 at a dose of 60 mg/kg BW/day.10 Hence, KAA dose used in our study was 600 mg 3 times daily.

Walser et al. showed that KAA supplementation at a dose of 6-14 g/day for 15-60 days in 10 patients of severe uremia produced no toxicity.11 Mitch et al. found no side-effect or toxicity of KAA supplementation in patients of CKD.12 Hence, the ADRs might be the manifestations of underlying renal pathology or due to other co-administered drugs.

The findings in our study are in accordance with those reported in previous studies. Hence, supplementation of KAA along with conservative management produces improvement in clinical features as well as biochemical parameters and safe in patients of CKD.

**CONCLUSION**

KAA supplementation improved the therapeutic effect of conservative management in patients of CKD.

**Funding:** No funding sources
**Conflict of interest:** None declared
**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int. 2007;72(3):247-59.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1-266.
3. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, et al. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013;14:114.
4. Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney Int Suppl. 2003(83):S115-8.
5. Chang JH, Kim DK, Park JT, Kang EW, Yoo TH, Kim BS, et al. Influence of ketoanalogs supplementation on the progression in chronic kidney disease patients who had training on low-protein diet. Nephrol (Carlton). 2009;14(8):750-7.
6. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. Cochrane Database Syst Rev. 2000(2):CD001892.
7. Haque SF, Ansari AP. Keto-analogues of essential amino acids improves the clinical outcome in patients with CKD. J Med Sci Res. 2011;2(2):64-6.
8. Teplan V. Supplements of keto acids in patients with chronic renal failure. Nefrol Derg. 2004;13(1):3-7.
9. Aparicio M, Gin H, Poutaux L, Bouchet JL, Morel D, Aubertin J. Effect of a ketoacid diet on glucose tolerance and tissue insulin sensitivity. Kidney Int Suppl. 1989;27:S231-5.
10. Chen JB, Cheng BC, Kao TW. A comparison of progression of chronic renal failure: low dose vs standard dose ketoacids. Kidney Res Clin Pract. 2012;31(2):A24.
11. Walser M, Coulter AW, Dighe S, Crantz FR. The effect of keto-analogues of essential amino acids in severe chronic uremia. J Clin Invest. 1973;52(3):678-90.
12. Mitch WE, Abras E, Walser M. Long-term effects of a new ketoacid-amino acid supplement in patients with chronic renal failure. Kidney Int. 1982;22(1):48-53.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1-266.
14. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
15. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.
16. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
17. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18(2):73-8.
18. Kher V. End-stage renal disease in developing countries. Kidney Int. 2002;62(1):350-62.
19. Richards P, Metcalfe-Gibson A, Ward EE, Wrong O, Houghton BJ. Utilisation of ammonia nitrogen for protein synthesis in man, and the effect of protein restriction and uraemia. Lancet. 1967;2(7521):845-9.
20. Ell S, Fynn M, Richards P, Halliday D. Metabolic studies with keto acid diets. Am J Clin Nutr. 1978;31(10):1776-83.
21. Chen N, Jin Y, Ren H, Jing X, Shen P, Huang X. Anti-inflammatory effects of low protein diet supplemented with keto-amino acid in the treatment of type 2 diabetic nephropathy. Kidney Res Clin Pract. 2012;31(2):A24.
22. Di Iorio BR, Minutolo R, De Nicola L, Bellizzi V, Catapano F, Iodice C, et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int. 2003;64(5):1822-8.

23. Bellizzi V, Di Iorio BR, De Nicola L, Minutolo R, Zamboli P, Trucillo P, et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2007;71(3):245-51.

24. Di Iorio B, Di Micco L, Torraca S, Sirico ML, Russo L, Pota A, et al. Acute effects of very-low-protein diet on FGF23 levels: a randomized study. Clin J Am Soc Nephrol. 2012;7(4):581-7.

25. Di Iorio BR, Bellizzi V, Bellasi A, Torraca S, D’Arrigo G, Tripepi G, et al. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. Nephrol Dial Transplant. 2013;28(3):632-40.

26. Marzocco S, Dal Piaz F, Di Micco L, Torraca S, Sirico ML, Tartaglia D, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif. 2013;35(1-3):196-201.

27. Garneata L, Mircescu G. Effect of low-protein diet supplemented with keto acids on progression of chronic kidney disease. J Ren Nutr. 2013;23(3):210-3.

28. Aparicio M, Cano NJ, Cupisti A, Ecder T, Fouque D, Garneata L, et al. Keto-acid therapy in predialysis chronic kidney disease patients: consensus statements. J Ren Nutr. 2009;19 5 Suppl: S33-5.

doi: 10.5455/2319-2003.ijbcp20140614

Cite this article as: Khan IA, Nasiruddin M, Haque SF, Khan RA. Clinical evaluation of efficacy and safety of α-keto analogs of essential amino acids supplementation in patients of chronic kidney disease. Int J Basic Clin Pharmacol 2014;3:484-9.